• Print this page
  • Text size medium
  • Text size large
Management Plan

Mitsubishi Chemical Holdings Corporation has formulated APTSIS 15, a five-year management plan through fiscal 2015. This new initiative is designed to foster growth, innovation, and a leap ahead by orchestrating the Group' s strengths.

Through APTSIS 15, MCHC is committed to running its business in a way that delivers KAITEKI solutions by putting the infinite potential of 'Good Chemistry' to work. This plan will retain the decision criteria set in APTSIS 10 in the drive to create a portfolio of high-performance, high-value-added businesses, while sustainably increasing corporate value.

Overview of APTSIS 15 (Fiscal 2011 – 2015)

(1) Business Strategy and Portfolio Categories

The new plan retains the growth, innovation, and leap ahead (M&A) strategies of APTSIS 10. The portfolio categories are next-generation growth business, growth business, cash-generating business, and business to be restructured.

TOP

(2) Key Numerical Targets

(Unit: Billions of yen, otherwise noted)

  Results forecasts
for fiscal 2010
Targets
for fiscal 2012
Targets
for fiscal 2015
Operating income ¥203 billion ¥230 billion ¥400 billion
Growth and innovation - - ¥330 billion
Leaping ahead (M&A) - - ¥70 billion
ROA* 4.6% - ≧ 8%以上
Net debt-to-equity ratio - - 1.0
Overseas sales ratio 34% - ≧ 45%

*ROA is calculated as income before income taxes and minority interests in consolidated subsidiaries
divided by average total assets.

Assumptions Results forecasts
for fiscal 2010
Fiscal
2011 - 2012
Fiscal
2013 - 2015
Naphtha price ¥45,600/kl ¥50,000/kl ¥55,000/kl
FOREX ¥85/US$ ¥80/US$

TOP

(3) Operating Income and Net Sales by Segment

(Unit: Billions of yen)

Business domain/Segment Results forecasts
for fiscal 2010
Targets
for fiscal 2012
Targets
for fiscal 2015
Performance Products 42 66 130
Electronics Applications 4 12 30
Designed Materials 38 54 100
Health Care 77 79 120
Industrial Materials 89 83 105
Chemicals 44 35 35
Polymers 45 48 70
Others 3 7 10
Corporate (8) (5) (5)
Contingency - - (30)
Subtotal 203 230 330
Operating income by leaping ahead
(M&A)
- - 70
Total 203 230 400
Net sales 3,190 3,600 4,200
Net sales by leaping ahead (M&A) - - 800
Total 3,190 3,600 5,000

TOP

(4) Investments and R&D

Invest decisively to realize growth and innovation during the next five years.

(Unit: Billions of yen)

Business domain/Segment Investments
(Planned investments)
R&D
Performance Products 440 210
Electronics Applications 120 70
Designed Materials 320 140
Health Care 150 410
Industrial Materials 320 90
Chemicals 120 30
Polymers 200 60
Corporate, and others 90 40
Total 1,000 750

Excluding resource allocation for leaping ahead (M&A)

TOP

(5) Strategies and Initiatives

Basic concept: "Grow, Innovate, and Leap Ahead by orchestrating the Group' s strengths"

i Strengthening Fundamentals

Generate synergies, improve financial position, and reform business structure.

ii Growth Strategy

Accelerate transformation to high-performance and high-value-added business portfolio by orchestrating the Group strengths.

  • ◆ Performance Products
    • ● Expand high-performance products and high-value-added businesses by integrating
           key technologies and know-how
    • ● Expand green businesses
    • ● Accelerate global expansion
  • ◆ Health Care
    • ● Strengthen sales of current major products by life cycle management
    • ● Rapidly maximize profit from new ethical drugs and increase approved products in
           USA, EU and PRC
    • ● Strengthen pipeline to fulfill unmet medical needs
  • ◆ Industrial Materials
    • ● Globalize operations and accelerate increasing value-added product ratio
            (strengthen ties with regional partners)
    • ● Balanced growth with product chain optimization
    • ● Complete restructuring in Japan

iii Innovation Strategy

Accelerate launch of new growth drivers.

  • ◆ Organic photovoltaic (OPV) modules and materials
  • ◆ Organic photo semiconductors
  • ◆ Advanced performance products
  • ◆ Agribusiness solutions
  • ◆ Healthcare solutions
  • ◆ Sustainable resources

iv Leaping Ahead (M&A)

Strategically allocate resources in alliances and acquisitions to expand businesses. Policies and priority areas are shown below.

  • ◆ Strengthen growth business and next-generation growth business
  • ◆ Accelerate global expansion
  • ◆ Performance Products and Health Care domains

TOP

(6) Strategies by Business Domain

i Performance Products

Accelerate launch of green businesses, pursue further value-added, and reach out to global markets.

  • ◆ Growth Strategy
    • ● Expand high-performance and value-added businesses
        Functional composite materials
        High-performance molding products
        Specialty chemicals
    • ● Expand green businesses
        White LED lighting materials
        Lithium-ion battery materials
    • ● Accelerate global operations
        FPD components
        Water treatment system and services
  • ◆ Innovation Strategy
    • ● Building and expanding new businesses for the future
        OPV modules and materials
        Organic photo semiconductors
        Advanced performance products
        Agribusiness solutions
  • ◆ Cash-Generating Business
    • ● Increase profit stability
        Recording media
        Performance films (Films and packaging containers)
        Food ingredients

ii Health Care

Accelerate to be a global research-driven pharmaceutical company and deliver healthcare solutions.

  • ◆ Growth Strategy (Ethical Drugs)
    • ● Strengthen sales of current major products by life cycle management
    • ● Rapidly maximize profit from new ethical drugs and increase approved products in
           USA, EU and PRC
    • ● Strengthen pipeline to fulfill unmet medical needs
  • ◆ Innovation Strategy (Healthcare Solutions)
    • ● Deliver healthcare solutions through pharmaceuticals and diagnostics
    • ● Collaboration among the Group’s healthcare-related operations
  • ◆ Cash-Generating Business
    • ● Stabilize earnings from cash-generating businesses
        Diagnostics and support for new pharmaceutical development
        Generics

iiiIndustrial Materials

Transform to profitable portfolio driven by accelerated global operation, shift to high-performance products, and implementation of optimized product chain.

  • ◆ Growth Strategy
    • ● Accelerate globalization and shift to high-performance products (strengthen ties with
           regional partners)
        MMA and PMMA
        Performance polymers
        High-performance graphite
  • ◆ Innovation Strategy
    • ● Deliver new materials that contribute to the environment and the sustainable carbon
           society
        Sustainable resources
  • ◆ Cash-Generating Business
    • ● Stabilize earnings and reinforce business structure
        Stabilize operations and minimize environmental impact
        Reinforce business structure by leveraging high-value-added products, expanding knowledge business and improving process technologies: purified terephthalic acid, coke, polypropylene, phleomycin, bisphenol-A, and polycarbonate
  • ◆ Business to Be Restructured
    • ● Complete restructuring in Japan
    • ● Restructuring of ethylene center and optimization of derivatives

           Take the following initiatives to respond to the anticipated 1) decrease in demand for
           derivatives (especially polyolefins), and 2) downsizing naphtha crackers, in
           accordance with threat from resource-producing nations.
        Derivatives
      1) Expand high-value added product line and take countermeasures
      2) Further optimization with partners
        Crackers (Mizushima)
      1) Unify naphtha cracker operations with Asahi Kasei and downsize capacity
      2) Consider a single cracker with Asahi Kasei and collaboration with refineries
        Crackers (Kashima)
      1) Increase competitiveness through regional partnership
      2) Further restructuring, including collaboration with refineries

TOP

(7) Global Operation

Expand overseas sales ratio and operating income margin (fiscal 2010 vs. fiscal 2015).
     Overseas sales ratio: From 34% to 45%
     Overseas operating income margin: From 26% to 50%

TOP

(8) Synergies

Plan to generate major synergies of ¥5 billion in fiscal 2012 and ¥15 billion in fiscal 2015 in carbon fibers and composites, water treatment, specialty chemicals, and others.

Plan to generate cost synergies of ¥6 billion in fiscal 2012 and ¥28 billion in fiscal 2015 in purchasing, logistics, IT, and R&D.

Expect to generate synergies of ¥11 billion in fiscal 2012 and ¥43 billion in fiscal 2015 in total.

TOP

(9) Enhancing Shareholder Value and Corporate Value

i Enhancing Shareholder Value

  • ◆Basic Policy
    • ◇ Enhance shareholder value by improving corporate value
  • ◆Shareholder Returns
    • ◇ Maintain sufficient internal reserves to fund business development while paying
           consolidated results–based dividends
    • ◇ While targeting a medium-term payout ratio of at least 30%, we will also prioritize
           stable dividends (maintaining and increasing cash dividends per share)

ii KAITEKI Indexes Notice

Implement KAITEKI indexes, including the Sustainability index, Health index, and Comfort index that MCHC has developed as part of its business management to monitor progress and manage plan-do-check-act cycles. Here are some concrete examples:

  • ◆Sustainability Index
    • ◇ Reduce environmental impact by 30% vs. 2005 levels and cut GHG emissions by
           17% vs. 2005 levels.
  • ◆Health Index
    • ◇ Increase index performance, derived from the degree of difficulty in treating diseases
           and the number of administered patients, by 30% vs. 2009.
  • ◆Comfort Index
    • ◇ Increase new product development ratio from 16% to 35% in the Performance
           Products and the Health Care domains by fiscal 2015.

TOP

The Mitsubishi Chemical Holdings Group Mid-term Management Plan, APTSIS 15

Dec. 8, 2010 APTSIS 15
Notice
[PDF: 2.06mb]
Transcript [PDF: 53.0kb]

TOP